Monopar Therapeutics Inc (MNPR)


Stock Price Forecast

Feb. 16, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Monopar Therapeutics Inc chart...

About the Company

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.

Employees

10

Exchange

NASDAQ

Website

www.monopartx.com

$M

Total Revenue

10

Employees

$30M

Market Capitalization

-3.00

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MNPR News

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

13d ago, source:

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative ...

Monopar Therapeutics Inc

24d ago, source: CNN

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development ...

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

26d ago, source: Business Insider

WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

28d ago, source: Yahoo Finance

About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing innovative treatments for cancer patients. Monopar's pipeline ...

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

21d ago, source: Yahoo Finance

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...

What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?

25d ago, source: Hosted on MSN

Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped during the trading session on Thursday on a strong volume session volume of 16.179 million, compared to an average volume of 1.817 million ...

Monopar Therapeutics Inc MNPR

21d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

20d ago, source: Stockhouse

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

Monopar Therapeutics Inc (MNPR)

18d ago, source: Investing

Monopar Therapeutics Inc . (Nasdaq: NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced... Monopar Therapeutics ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...